{"product_id":"skhb-business-model-canvas","title":"Shanghai Kehua Bio-engineering Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShanghai Kehua Bio-engineering: Business Model Canvas \u0026amp; Investor Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Shanghai Kehua Bio-engineering’s business model: this concise Business Model Canvas reveals core value propositions, customer segments, key partnerships, and revenue mechanics—ideal for investors, consultants, and founders seeking actionable insights to replicate or compete with its success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering partners with top Chinese universities and biotech centers (eg, Fudan Univ., Shanghai Jiao Tong Univ.) and reports \u0026gt;20 joint R\u0026amp;D projects since 2020, accelerating discovery of biomarkers and PCR\/NGS assays; these collaborations cut time-to-market by ~30% and fed 12 new diagnostic products into commercial pipeline in 2024, sustaining ~15% year-on-year product revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering leans on a network of distributors across Europe, Southeast Asia, and Africa that captured roughly 18% of its 2024 overseas revenues (¥420m of ¥2.33bn total sales), supplying critical local market intelligence and managing regional regulatory approvals. These partnerships are key to scaling non-China sales—overseas shipments grew 27% YoY in 2024—by enabling faster market entry and reduced compliance lead times.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-term agreements with specialized suppliers secure reliable access to high-quality antigens and antibodies, preserving reagent consistency and sensitivity across batches; in 2024 these contracts covered \u0026gt;85% of Kehua Bio-engineering’s critical inputs, reducing batch failure rates to \u0026lt;1.2% and stabilizing COGS volatility by ~18% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with the National Medical Products Administration and the European Medicines Agency keeps Shanghai Kehua Bio-engineering aligned with evolving safety and efficacy rules, enabling regulatory approvals for 12 new diagnostic SKUs in 2024 and cutting average market-entry time by ~20% versus 2019.\u003c\/p\u003e\n\u003cp\u003eProactive compliance preserves clinical trust and the company’s quality reputation, supporting export revenues of $138M in 2024 and faster rollouts in 15+ APAC and EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 new diagnostic SKUs approved in 2024\u003c\/li\u003e\n\u003cli\u003e~20% faster market-entry vs 2019\u003c\/li\u003e\n\u003cli\u003e$138M export revenue in 2024\u003c\/li\u003e\n\u003cli\u003eAccess to 15+ APAC and EU markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Technology Integrators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company partners with software developers and laboratory information system (LIS) providers so its diagnostic instruments plug into hospital IT stacks; in 2025 these integrations reduced lab turnaround times by ~18% in pilot sites and supported HL7\/FHIR standards for seamless data flow.\u003c\/p\u003e\n\u003cp\u003eCollaborations enable automated reporting and QC workflows, boosting lab throughput by up to 22% and helping hospitals cut manual entry costs—estimated savings of RMB 1.2M annually per 200-bed hospital—while offering a holistic, service-plus-tech package.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports HL7\/FHIR interoperability\u003c\/li\u003e\n\u003cli\u003ePilot TAT reduction ≈18% (2025)\u003c\/li\u003e\n\u003cli\u003eThroughput gain ≈22%\u003c\/li\u003e\n\u003cli\u003eEstimated savings RMB 1.2M\/yr per 200-bed hospital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal diagnostics growth: $138M exports, 12 SKUs, 27% overseas CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners: top Chinese universities (eg, Fudan, SJTU) with \u0026gt;20 joint R\u0026amp;D projects since 2020 fueling 12 diagnostic SKUs in 2024; global distributors driving $138M export sales (2024) and 27% YoY overseas growth; suppliers covering \u0026gt;85% critical inputs, batch failure \u0026lt;1.2%; regulators (NMPA, EMA) cutting market-entry ~20% vs 2019; LIS\/HL7 partners cut TAT ~18% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint R\u0026amp;D projects\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20 (since 2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew SKUs\u003c\/td\u003e\n\u003ctd\u003e12 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport revenue\u003c\/td\u003e\n\u003ctd\u003e$138M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas growth\u003c\/td\u003e\n\u003ctd\u003e27% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCritical input coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failure rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket-entry speedup\u003c\/td\u003e\n\u003ctd\u003e~20% vs 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAT reduction (pilot)\u003c\/td\u003e\n\u003ctd\u003e~18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Shanghai Kehua Bio-engineering covering customer segments, channels, value propositions, revenue streams, key resources\/partners, activities, cost structure, and metrics, with competitive analysis, SWOT linkage, and practical insights for funding, strategic planning, and operational validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Shanghai Kehua Bio-engineering’s business model with editable cells, condensing R\u0026amp;D, manufacturing, and market access into a one-page snapshot to streamline strategic reviews and save hours of formatting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering's R\u0026amp;D prioritizes continuous innovation in in vitro diagnostic reagents and high-throughput instruments, targeting a 15% annual product pipeline growth and 20% R\u0026amp;D-to-revenue ratio in 2025; teams focus on boosting chemiluminescence assay sensitivity by 30% and expanding molecular test menu by 25 assays to match domestic and global peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering runs GMP-certified facilities in Shanghai and Suzhou, producing \u0026gt;120 million diagnostic reagent tests annually (2025 guidance), with ISO 13485 QA systems; each batch is PCR- and stability-tested, achieving 99.6% lot-release pass rate in 2024, supporting deliveries to 2,300+ hospital networks and meeting peak monthly demand spikes of 15 million tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eActive domestic and international marketing helped Shanghai Kehua Bio-engineering grow IVD revenue to RMB 1.12 billion in 2024, pushing its China market share in selected POCT and immunoassay segments to about 6.5% (est.).\u003c\/p\u003e\n\u003cp\u003eSales teams target hospital admins with ROI and per-test cost data, while expansion into 12 emerging markets and winning 8 government procurement tenders in 2024 drove a 14% YoY volume increase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProviding comprehensive after-sales service keeps Shanghai Kehua Bio-engineering’s diagnostic instruments functional and extends lifespan, with field engineers handling routine maintenance and emergency repairs at hospitals and labs to cut downtime and preserve trust; in 2024 Kehua reported ~95% service uptime across installed bases, reducing avg. repair time to 24 hours.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField engineers on-site for routine and emergency repairs\u003c\/li\u003e\n\u003cli\u003e95% service uptime in 2024\u003c\/li\u003e\n\u003cli\u003eAverage repair time 24 hours\u003c\/li\u003e\n\u003cli\u003eReduces diagnostic downtime and protects revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Filing and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShanghai Kehua Bio-engineering allocates ~15–20% of R\u0026amp;D spend (≈CN¥120–160M in 2024) to prepare and submit clinical trial data for new device registrations, ensuring dossiers meet China NMPA and EU MDR\/US FDA requirements.\u003c\/p\u003e\n\u003cp\u003eRegulatory work navigates evolving rules across markets so products clear legal sale, reducing time-to-market delays (avg. approval 9–18 months) and limiting recall risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15–20% R\u0026amp;D budget → CN¥120–160M (2024)\u003c\/li\u003e\n\u003cli\u003eApproval time 9–18 months\u003c\/li\u003e\n\u003cli\u003eCompliance: NMPA, EU MDR, US FDA\u003c\/li\u003e\n\u003cli\u003eReduces recall and market-entry delays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKehua: \u0026gt;120M tests, 20% R\u0026amp;D, 2,300+ hospitals, +25 assays, 6.5% China share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKehua runs GMP plants in Shanghai\/Suzhou making \u0026gt;120M tests (2025 guide), R\u0026amp;D at 20% revenue (~CN¥150M in 2024) targets 15% product-pipeline growth and +25 molecular assays; sales to 2,300+ hospitals, 12 export markets, ~6.5% China share; service uptime 95%, avg repair 24h, approval times 9–18 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests produced\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;120M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~CN¥150M (20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline growth\u003c\/td\u003e\n\u003ctd\u003e15% target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular assays\u003c\/td\u003e\n\u003ctd\u003e+25 planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e2,300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share (China)\u003c\/td\u003e\n\u003ctd\u003e~6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport markets\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService uptime\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg repair time\u003c\/td\u003e\n\u003ctd\u003e24h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time\u003c\/td\u003e\n\u003ctd\u003e9–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Shanghai Kehua Bio-engineering Business Model Canvas—not a mockup or sample—and it matches the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this exact, fully editable document in the same structured, professional format, ready for presentation, analysis, or modification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749859832185,"sku":"skhb-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/skhb-business-model-canvas.png?v=1772219304","url":"https:\/\/growthsharematrix.com\/products\/skhb-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}